| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-32,436 | -47,269 | 12,791 | -5,521 | -2,864 | -1,107 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
34,276 | 16,802 | 9,512 | 5,115 | 3,933 | 1,817 | |
Amortization of deferred financing costs and debt discount | ||||||
10,877 | 103 | 92 | 1,279 | 2,148 | 259 | |
Payment of imputed interest on debt | ||||||
- | - | - | 3,893 | 105 | 13 | |
Deferred taxes | ||||||
-16,353 | -3,648 | -9,467 | 498 | 290 | -422 | |
Issuance of common stock warrants | ||||||
- | - | - | - | 16 | 31 | |
Stock-based compensation | ||||||
27,278 | 10,361 | 8,752 | 4,250 | 565 | 254 | |
Change in fair value of warrant liability | ||||||
- | - | - | -639 | 2,786 | 269 | |
Change in fair value of acquisition-related contingent consideration | ||||||
3,816 | 49,468 | -6,173 | -338 | -2,059 | 790 | |
Acquisition-related contingent consideration paid | ||||||
24,480 | - | - | - | - | - | |
Change in fair value of acquisition-related consideration | ||||||
- | - | - | 55 | - | - | |
Loss on extinguishment of debt | ||||||
- | - | - | -6,411 | - | - | |
Write-off in-process software development costs | ||||||
- | - | - | - | - | 63 | |
Other noncash items | ||||||
-20 | -51 | -18 | - | 10 | - | |
Changes in operating assets and liabilities, net of effect from acquisitions: | ||||||
Accounts receivable, net | ||||||
-1,444 | 9,456 | 1,765 | 756 | 1,711 | 1,388 | |
Inventories | ||||||
106 | 799 | -116 | 607 | 264 | 792 | |
Rebates receivable | ||||||
- | - | - | - | 96 | 715 | |
Prepaid expenses and other current assets | ||||||
7,705 | 1,651 | -295 | 783 | 259 | 77 | |
Other assets | ||||||
269 | 460 | 187 | -1 | 4 | 30 | |
Acquisition-related contingent consideration | ||||||
- | - | - | - | -610 | -60 | |
Accounts payable | ||||||
-7,809 | -778 | 1,288 | 665 | 440 | 1,383 | |
Accrued expenses and other liabilities | ||||||
5,712 | 2,599 | 2,626 | -1,168 | 1,060 | 604 | |
Other long-term liabilities | ||||||
-80 | 507 | 410 | 2,205 | - | 4 | |
Net cash used in operating activities | ||||||
-5,815 | 15,830 | 18,308 | 6,774 | 3,256 | 870 | |
Cash flows from investing activities: | ||||||
Purchases of property and equipment | ||||||
7,474 | 4,988 | 3,303 | 3,813 | 234 | 230 | |
Software development costs | ||||||
14,487 | 5,558 | 3,314 | 1,854 | 940 | 738 | |
Purchases of intangible assets | ||||||
1,202 | 30 | - | 29 | - | - | |
Issuance of note receivable | ||||||
- | 1,000 | - | - | - | - | |
Proceeds from repayment of note receivable | ||||||
1,000 | - | - | - | - | - | |
Change in restricted cash | ||||||
- | - | - | - | -300 | 500 | |
Acquisitions of businesses, net of cash acquired | ||||||
158,762 | 32,232 | 34,451 | 5,400 | 2,403 | 13,448 | |
Net cash used in investing activities | ||||||
-180,925 | -43,808 | -41,068 | -11,096 | -3,277 | -14,916 | |
Cash flows from financing activities: | ||||||
Payments for repurchase of common stock | ||||||
- | 2,866 | 959 | - | - | - | |
Proceeds from exercise of stock options | ||||||
3,702 | 3,523 | 480 | 153 | 12 | 59 | |
Proceeds from disgorgement of short swing profits | ||||||
- | 156 | - | - | - | - | |
Payments for employee taxes for shares withheld | ||||||
- | - | 2,123 | - | - | - | |
Payments for debt financing costs | ||||||
9,630 | 175 | 221 | 1,521 | 69 | 212 | |
Proceeds from notes payable to related parties | ||||||
- | - | - | - | - | 100 | |
Repayments of notes payable to related parties | ||||||
- | - | - | 250 | 354 | 175 | |
Borrowings on line of credit | ||||||
- | 45,000 | 35,342 | 6,000 | 10,000 | - | |
Repayments of line of credit | ||||||
45,000 | - | 35,342 | 16,000 | 6,860 | - | |
Repayment of note payable related to acquisition | ||||||
- | - | - | 14,337 | - | - | |
Payments of equity offering costs | ||||||
- | 364 | 365 | 3,346 | 481 | - | |
Payments of acquisition-related contingent consideration | ||||||
29,062 | 1,646 | 2,098 | 1,895 | 267 | 440 | |
Payments of acquisition-related consideration | ||||||
- | - | - | 180 | 1,895 | 487 | |
Repayments of long-term debt and finance leases | ||||||
968 | 1,051 | 766 | - | - | - | |
Proceeds from issuance of convertible senior subordinated notes | ||||||
325,000 | - | - | - | - | - | |
Proceeds from sale of warrants | ||||||
65,910 | - | - | - | - | - | |
Purchase of convertible note hedges | ||||||
101,660 | - | - | - | - | - | |
Proceeds from long-term debt | ||||||
- | - | - | 30,000 | - | 15,000 | |
Repayments of long-term debt | ||||||
- | - | - | 47,369 | 2,161 | 1,704 | |
Proceeds from issuance of common stock, net of underwriting costs | ||||||
- | - | 34,897 | 55,186 | - | - | |
Net cash provided by financing activities | ||||||
208,292 | 42,577 | 28,845 | 6,441 | -2,075 | 12,141 | |
Net (decrease) increase in cash and restricted cash | ||||||
21,552 | 14,599 | 6,085 | 2,119 | -2,096 | -1,905 | |
Supplemental disclosure of cash flow information: | ||||||
Acquisition of equipment under capital leases | ||||||
- | 442 | 50 | 1,605 | 373 | 326 | |
Purchases of property and equipment and software development included in accounts payable and accrued expenses | ||||||
19 | 175 | 540 | 373 | 46 | 53 | |
Deferred offering costs included in accounts payable | ||||||
- | - | 355 | 132 | 1,817 | - | |
Cash paid for interest | ||||||
3,181 | 720 | 599 | 8,457 | 2,409 | 1,080 | |
Cash paid for taxes | ||||||
381 | - | - | - | - | - | |
Interest costs capitalized to property and equipment and software development costs | ||||||
321 | - | - | - | - | - | |
Decretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | - | -2,439 | 9,966 | - | |
Stock issued in connection with acquisitions | ||||||
9,504 | 11,471 | 11,541 | 4,500 | - | - | |
Accretion of redeemable convertible preferred stock | ||||||
- | - | - | - | - | 3,884 | |
Fair value of promissory notes entered into connection with Medliance acquisition | ||||||
- | - | - | - | - | 14,347 | |
Fair value of preferred stock warrants issued to lender | ||||||
- | - | - | - | - | 1,835 | |